Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV
Renovaro Inc. (NASDAQ: RENB) has appointed Maurice van Tilburg, its current Chairman of the Board, as Chief Executive Officer of its subsidiary GEDi Cube BV, a company specializing in AI-driven cancer diagnostics. Van Tilburg brings extensive experience from his previous roles, including Director of the Dutch National Growth Fund where he managed €11B in government investments, and CEO of Euronext Amsterdam. In his new position, he will focus on commercializing technologies, advancing partnerships with Nebul for early cancer detection, and leading the Lumina project for lung cancer Minimal Residual Disease detection. The appointment aims to accelerate GEDi Cube's development pipeline and create value through various products and services in cancer diagnostics and therapeutics.
Renovaro Inc. (NASDAQ: RENB) ha nominato Maurice van Tilburg, attuale Presidente del Consiglio di Amministrazione, come Amministratore Delegato della sua sussidiaria GEDi Cube BV, un'azienda specializzata nella diagnostica oncologica tramite intelligenza artificiale. Van Tilburg porta una vasta esperienza dai suoi ruoli precedenti, tra cui Direttore del Fondo Nazionale per la Crescita olandese, dove ha gestito 11 miliardi di euro in investimenti pubblici, e CEO di Euronext Amsterdam. Nella sua nuova posizione, si concentrerà sulla commercializzazione delle tecnologie, sull'avanzamento delle collaborazione con Nebul per la rilevazione precoce del cancro e sulla guida del progetto Lumina per la rilevazione della Malattia Residua Minima nel cancro ai polmoni. La nomina mira ad accelerare la pipeline di sviluppo di GEDi Cube e a creare valore attraverso vari prodotti e servizi nella diagnostica e nella terapia oncologica.
Renovaro Inc. (NASDAQ: RENB) ha nombrado a Maurice van Tilburg, actual Presidente de la Junta Directiva, como Director Ejecutivo de su subsidiaria GEDi Cube BV, una empresa especializada en diagnósticos de cáncer impulsados por IA. Van Tilburg aporta una amplia experiencia de sus roles anteriores, incluido el de Director del Fondo Nacional de Crecimiento de los Países Bajos, donde gestionó 11 mil millones de euros en inversiones gubernamentales, y CEO de Euronext Ámsterdam. En su nuevo cargo, se enfocará en la comercialización de tecnologías, en avanzar asociaciones con Nebul para la detección temprana del cáncer y en liderar el proyecto Lumina para la detección de la Enfermedad Residual Mínima en cáncer de pulmón. La designación tiene como objetivo acelerar la cartera de desarrollo de GEDi Cube y crear valor a través de diversos productos y servicios en diagnósticos y terapias oncológicas.
Renovaro Inc. (NASDAQ: RENB)는 현재 이사회 의장인 Maurice van Tilburg를 자회사 GEDi Cube BV의 CEO로 임명했습니다. 이 회사는 인공지능 기반의 암 진단을 전문으로 하고 있습니다. Van Tilburg는 네덜란드 국가 성장 기금 이사로서 110억 유로의 정부 투자를 관리한 경험을 포함하여 광범위한 경력을 보유하고 있으며, 유로넥스트 암스테르담의 CEO로도 활동했습니다. 새로운 직위에서 그는 기술 상용화, 조기 암 진단을 위한 Nebul과의 파트너십 발전, 폐암 최소 잔류 질병 탐지를 위한 Lumina 프로젝트를 이끌게 됩니다. 이번 임명의 목적은 GEDi Cube의 개발 파이프라인을 가속화하고 암 진단 및 치료를 위한 다양한 제품과 서비스로 가치를 창출하는 것입니다.
Renovaro Inc. (NASDAQ: RENB) a nommé Maurice van Tilburg, l'actuel Président du Conseil d'Administration, comme Directeur Général de sa filiale GEDi Cube BV, une entreprise spécialisée dans le diagnostic du cancer basé sur l'IA. Van Tilburg apporte une vaste expérience de ses précédents rôles, y compris celui de Directeur du Fonds National de Croissance néerlandais, où il a géré 11 milliards d'euros d'investissements publics, et de PDG d'Euronext Amsterdam. Dans son nouveau poste, il se concentrera sur la commercialisation des technologies, le développement de partenariats avec Nebul pour la détection précoce du cancer, et la direction du projet Lumina pour la détection des maladies résiduelles minimales liées au cancer du poumon. Cette nomination vise à accélérer la pipeline de développement de GEDi Cube et à créer de la valeur à travers divers produits et services en matière de diagnostic et de thérapies contre le cancer.
Renovaro Inc. (NASDAQ: RENB) hat Maurice van Tilburg, den derzeitigen Vorsitzenden des Vorstands, zum Vorstandsvorsitzenden seiner Tochtergesellschaft GEDi Cube BV ernannt, einem Unternehmen, das sich auf KI-gestützte Krebsdiagnostik spezialisiert hat. Van Tilburg bringt umfangreiche Erfahrungen aus seinen früheren Positionen mit, darunter als Direktor des niederländischen Nationalen Wachstumsfonds, wo er 11 Milliarden Euro an staatlichen Investitionen verwaltete, und als CEO von Euronext Amsterdam. In seiner neuen Rolle wird er sich darauf konzentrieren, Technologien zu kommerzialisieren, Partnerschaften mit Nebul für die frühzeitige Krebsdiagnose voranzutreiben und das Lumina-Projekt zur Erkennung von Minimal Residual Disease bei Lungenkrebs zu leiten. Die Ernennung soll die Entwicklungspipeline von GEDi Cube beschleunigen und Wert durch verschiedene Produkte und Dienstleistungen in der Krebsdiagnostik und -therapie schaffen.
- Appointment of experienced executive with significant capital markets and technology background
- Leader with proven track record in managing large investment portfolios (€11B at Dutch National Growth Fund)
- Strategic focus on commercialization of cancer diagnostic technologies
- None.
Current Renovaro Chairman to Lead Subsidiary’s Development Program and Commercialization
LOS ANGELES and AMSTERDAM, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced Chairman of the Board, Maurice van Tilburg, has been appointed as Chief Executive Officer of its subsidiary GEDi Cube BV (a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies) DBA RenovaroCube.
Maurice van Tilburg has held several senior positions in the Financial Services industry and Tech enterprises combining general management, technology, operational service delivery, financial management, audit and product development. In conjunction with the appointment, Mr. van Tilburg recently retired as the Director of the Dutch National Growth Fund where he oversaw a total of more than
“We are privileged that our Chairman Maurice van Tilburg has accepted the position of Chief Executive Officer of GEDi Cube BV, bringing a deep understanding of both Renovaro and GEDi Cube BV,” said David Weinstein, Chief Executive Officer of Renovaro. “His expertise in technology and the capital markets will enable us to prioritize commercializing our technologies. He will take the lead in partnerships with Nebul to advance the early detection of cancer and other diseases, and the Lumina project which aims to deliver an advanced Minimal Residual Disease (MRD) detection platform for lung cancer. Maurice will be instrumental in steering us in our next stage of growth and GEDi Cube’s BV development pipeline to create value streams from a broad range of products and services.”
"I am thrilled to have the opportunity to lead GEDi Cube BV into its next exciting phase of development,” said Maurice van Tilburg “I believe that the transformative AI Cube platform will be an inflection point in the creation of diagnostics for early-stage cancer and identifying new genes for our Cancer Vaccine Platform. I look forward to working closely with the GEDiCube executive team to harness the power of multi-omics biomarkers and AI-driven technology with the aim to transform recurrence risk prediction and treatment strategies for millions of patients worldwide.”
Renovaro’s Board of Directors unanimously approved the appointment of Maurice van Tilburg as CEO of GEDi Cube BV.
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
About GEDi Cube BV
DBA RenovaroCube is a pioneer in AI-based molecular diagnostics, committed to revolutionizing healthcare through advanced data analysis. Its platform integrates cutting-edge AI capabilities with state-of-the-art HPC infrastructure to provide unparalleled insights into multi-omic data for early detection of diseases based on non-invasive testing using liquid biopsy(blood)
RenovaroCube’s AI platform is purpose-built to process and analyze multi-omic molecular data, facilitating the discovery of biomarkers critical for early cancer detection, monitoring, and treatment personalization. Originally developed for the fintech sector, this platform is being reengineered for healthcare, offering:
- Sequence Processing: Transform raw molecular data from patient samples into clean, analyzable formats using advanced sequencing and alignment technologies, ensuring the highest quality for downstream analysis.
- Biomarker Discovery: Harness unique algorithms and multi-omic pipelines to identify biologically relevant cancer biomarkers, providing critical insights into disease mechanisms and potential therapeutic targets.
- AI Factory: Employ sophisticated machine learning models to predict cancer presence, origin, and stage based on extracted biomarker features. These models are trained on vast datasets to enhance accuracy and reliability, supporting early detection and personalized treatment strategies.
- Precision Diagnostics: Offer an interactive interface for visualizing data, generating comprehensive clinical reports, and delivering actionable insights across various omic layers and biomarkers. This interface empowers healthcare professionals to make informed decisions with confidence.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us
For media inquiries, please contact:
karen@renovarocube.com and STarsh@Renovarogroup.com
FAQ
What is the significance of Maurice van Tilburg's appointment as CEO of GEDi Cube BV for RENB shareholders?
What major projects will GEDi Cube BV focus on under van Tilburg's leadership?
What experience does Maurice van Tilburg bring to RENB's GEDi Cube BV?
How will GEDi Cube BV's AI technology be utilized under the new leadership?
